I-MAB

I-MAB

World Rank (Jan-05-2024)
18,548
Market Cap (Jan-05-2024)
0.177 Billion USD
World Rank (Jul-30-2023)
17,107
Market Cap (Jul-30-2023)
0.238 Billion USD
World Rank (Jan-07-2022)
4,633
Market Cap (Jan-07-2022)
3.176 Billion USD
World Rank (Jan-01-2021)
4,016
Market Cap (Jan-01-2021)
3.324 Billion USD
Headquarters Country
China
Nasdaq / NYSE Code
IMAB
Employee Count
228
Employee Count as of Date
As on 2020
World Region
Asia
World Subregion
Eastern Asia
Annual Revenue in USD
13 Million USD
Annual Net Income in USD
-339 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
815 Million USD
Total Liabilities in USD
151 Million USD
Total Equity in USD
663 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Biopharmaceutical
Biotechnology
Company Website
I-MAB
Yahoo
Yahoo @ Nasdaq
Company Profile
I-Mab is a Clinical Stage Biopharmaceutical company. It is committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company annual revenue is 114.5 million USD. The headquarters is in China.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share